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Asthma is a very common chronic inﬂammatory disease that
involves the respiratory system, whereby the airways occa-
sionally constrict, become inﬂamed, and become lined with
excessive mucus, often in response to inhaled allergens (1). In
terms of the development of asthma, airway immune dys-
function to inhaled allergens is critical for the initiation and
orchestration of the inﬂammatory responses in asthmatic air-
ways (2, 3). The default immune response to the inhalation
of innocuous proteins (allergens) is nonresponsiveness (i.e.,
tolerance) to allergens (4, 5). As inhaled allergens are ubiqui-
tous in the environment, it remains unclear as to why some
individuals develop immune dysfunction to allergens, whereas
others do not. Household dust allergens are contaminated
with lipopolysaccharide (LPS), which is a cell wall compo-
nent of Gram-negative bacteria and ubiquitously present in
the environment (6). Lipopolysaccharide is one of the patho-
gen-associated molecular patterns (PAMPs) that produce
pro-inﬂammatory and immune-modulating mediators (4, 6).
In recent studies, we showed that airway sensitization with
LPS-containing allergens induced noneosinophilic inﬂamma-
tion as the result of mixed Th1 and Th17 cell responses to
inhaled allergens (7, 8). We also showed that following
airway exposure to LPS, the up-regulation of immune-modu-
lating cytokines, such as IL-12p70 and IL-6, plays a key role
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Abstract
Background: Previous evidence indicates that inhalation of lipopolysaccharide
(LPS)-containing with allergens induced mixed Th1 and Th17 cell responses in the
airways. Extracellular vesicles (EVs) are nanometer-sized spherical, lipid-bilayered
structures and are recently in the public eye as an intercellular communicator in
immune responses.
Objective: To evaluate the role of EVs secreted by LPS inhalation in the develop-
ment of airway immune dysfunction in response to allergens.
Methods: Extracellular vesicles in bronchoalveolar lavage ﬂuids of BALB/c mice
were isolated and characterized 24 h after applications to the airway of 10 lgo f
LPS for 3 days. To evaluate the role of LPS-induced EVs on the development of
airway immune dysfunction, in vivo and in vitro experiments were performed using
the isolated LPS-induced EVs.
Results: The inhalation of LPS enhanced EVs release into the BAL ﬂuid, when
compared to the application of PBS. Airway sensitization with allergens and LPS-
induced EVs resulted in a mixed Th1 and Th17 cell responses, although that with
allergens and PBS-induced EVs induced immune tolerance. In addition, LPS-
induced EVs enhanced the production of Th1- and Th17-polarizing cytokines
(IL-12p70 and IL-6, respectively) by lung dendritic cells. Moreover, the immune
responses induced by the LPS-induced EVs were blocked by denaturation of the
EV-bearing proteins.
Conclusion: These data suggest that EVs (especially, the protein components)
secreted by LPS inhalation are a key intercellular communicator in the development
of airway immune dysfunction to inhaled LPS-containing allergens.
Allergy
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tively (7, 8).
In multicellular organisms, intercellular communication
between cells has been regarded to involve the secretion of
soluble factors that subsequently bind to receptors on
neighboring cells. Another mode of intercellular communi-
cation, the release of extracellular vesicles (EVs), has
recently attracted interest (9). Extracellular vesicles are
composed of a lipid bilayer that contains transmembrane
proteins and encloses soluble hydrophilic components
derived from the cytoplasm of the donor cells (9, 10).
Depending on cellular sources of EVs, they have been
suggested to have diverse immunologic functions; antigen-
presenting cell–derived EVs play a role in antigen delivery
and T-cell activation, and epithelial cell–derived EVs in
tolerance induction (9, 11).
In the present study, we hypothesized that, in addition to
the production of soluble mediators, host cells induce
immune dysfunction through the secretion of EVs after expo-
sure to LPS-containing allergens. To test this hypothesis, EVs
secreted after airway exposure to LPS in vivo, in combination
with allergens, were applied to the airways of naı¨ve mice. We
found that airway exposure of LPS enhanced the secretion of
EVs, which were derived from airway epithelial cells and
inﬂammatory cells. Interestingly, we found that airway sensi-
tization with LPS-induced EVs, together with allergens,
induced noneosinophilic lung inﬂammation, which is
related to mixed Th1 and Th17 cell responses. Moreover,
LPS-induced EVs increased the production levels of both
Th1- and Th17-polarizing cytokines (IL-12p70 and IL-6,
respectively) by lung dendritic cells (DCs). These results sug-
gest that EVs derived from host cells play a key role in the
intercellular communication in the development of airway
immune dysfunction to LPS-containing allergens.
Methods
Mice
BALB/c mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). Mice were bred in the pathogen-
free facilities at Pohang University of Science and Technol-
ogy (POSTECH). All live animal experiments were approved
by the POSTECH Ethics Committee.
Reagents
Lipopolysaccharide was purchased from Calbiochem (La
Jolla, CA, USA). Ovalbumin (OVA), polymyxin B (PMB),
and Protease K were obtained from Sigma–Aldrich (St.
Louis, MO, USA), and phenylmethylsulfonyl ﬂuoride from
Bio-Rad Laboratories (Hercules, CA, USA). Antibodies
(Abs) used for detecting EV in western blots were: anti-
mouse CD81 (Eat-2 clone; Biolegend, San Diego, CA, USA);
anti-mouse ICAM-1 (NS0 clone; R&D Systems, Minneapolis,
MN, USA); anti-mouse MHC II (IBL-5/22; Santa Cruz
Biotechnology, Santa Cruz, CA, USA); anti-mouse surfactant
protein-B (SPB02 clone; Abcam, Cambridge, MA, USA).
Abs used for FACS analysis were obtained from eBioscience
(San Diego, CA, USA).
Isolation of EVs
Female BALB/c (6–8 weeks of age) mice were anesthetized
with ketamine and xylazine and administrated intranasally
with 30 ll PBS with or without LPS (10 lg) on Days 0, 1,
and 2 (Fig. 1A). Bronchoalveolar lavage (BAL) ﬂuids were
taken 24 h after the last application, and then pooled. The
pooled BAL ﬂuids were diluted with PBS, and then centri-
fuged once at 500 g for 10 min and once at 3000 g for
20 min. To enrich for EVs, the supernatant was loaded onto
0.8 M and 2.5 M sucrose cushions in PBS (pH 7.2) and then
subjected to ultracentrifugation at 100 000 g for 2 h. After
centrifugation, the interface of the 0.8 M and 2.5 M sucrose
layers was collected and diluted 10-fold in PBS. The sucrose
cushion ultracentrifugation procedure was then repeated. The
collected interface was diluted 10-fold in PBS and subjected
to ultracentrifugation at 100 000 g for 2 h. Finally, the pellet
was resuspended in PBS, and the protein concentration was
determined using the Bradford dye assay (Bio-Rad Laborato-
ries, Hercules, CA, USA). EV proteins (2 lg) were analyzed
by SDS-PAGE and western blotting or coated beads for
FACS analysis, as previously described (11).
Electron microscopy (EM)
The puriﬁed EVs were applied to 400-mesh carbon-coated
copper grids (EMS, Matﬁeld, PA, USA). After allowing the
EV to absorb for 3 min, the samples were stained with 2%
uranylacetate (Ted Pella, Redding, CA, USA), and then
electron micrographs were recorded using the JEM 1011
1010 microscope (Jeol, Japan) at an acceleration voltage of
100 kV.
Limulus amebocyte lysate (LAL) assay to evaluate LPS
contamination
To evaluate LPS contamination in the isolated EVs, PBS-
and LPS-induced EVs (5 lg) or different doses of LPS, as a
standard, were made to react with LAL assay kit (QCL-1000;
Lonza, Basel, Switzerland) following an instruction manual.
To exclude LPS from the LPS-induced EVs, PMB (10 ng/ml)
were pretreated with PBS or LPS-induced EVs (0.5 lg/ml).
Heat inactivation and pretreatment of protease K
The isolated EVs were incubated at 99 C for 20 min and then
treated with chilled ice for 20 min to denaturalize proteins in
EVs. To denature surface proteins in EVs, EVs were pretreat-
ed with protease K (10 lg/ml) for 15 min and then neutral-
ized with phenylmethylsulfonyl ﬂuoride (1 mM).
In vitro evaluation of EV functions
To evaluate the pro-inﬂammatory activity in vitro, RAW
264.7 cells (3 · 10
5 cells/well), macrophage cell line, were
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Figure 1 The production of extracellular vesicles (EVs) is enhanced
by airway application of LPS, when compared with PBS application.
(A) Protocol for EV preparation. (B) Transmission electron micros-
copy (TEM) images of EVs derived from the Bronchoalveolar lavage
(BAL) ﬂuids of PBS-treated (a) and LPS-treated (b) mice (N =2 0
each group). (C) The amounts and numbers of EVs in the BAL ﬂuids
of PBS-treated and LPS-treated mice. The amounts of EVs were
quantiﬁed on the basis of protein concentrations, as measured
using the Bradford assay. The numbers of EVs were determined
by counting the EVs in the TEM images. (D) The levels of LPS in
the EVs isolated from the BAL ﬂuids of LPS-treated and PBS-trea-
ted mice. (E) Western blotting assessment of the levels of host
cell marker proteins, CD81, ICAM-1, surfactant protein B (SP-B),
and MHC class II, in the EVs derived from LPS-treated and
PBS-treated BALB/c mice. (F) FACS data of LPS- and PBS-induced
EVs for the expression levels of the airway epithelial cell marker
protein surfactant protein B (SP-B) and inﬂammatory cell marker
proteins, MHC class II, CD11b, and CD11c. For (D–F): EV_PBS, EVs
from PBS-treated mice; EV_LPS: EVs from LPS-treated mice.
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PBS- or LPS-induced EVs (0.5 lg/ml). The levels of
pro-inﬂammatory cytokines, such as IL-6 and TNF-a,
were quantiﬁed from conditioned media 6 h after the incu-
bation.
In vivo evaluation of EV functions
To evaluate the activities of EVs in the development of adap-
tive immune responses to inhaled allergens, 6-week-old mice
were sensitized intranasally with 1 lg PBS or LPS-induced
EVs and 75 lg of OVA on Days 0, 1, 2, and 7, and then
challenged with 50 lg of OVA alone on days 14, 15, 21, and
22. Allergen-speciﬁc adaptive immune responses were evalu-
ated 24 h after the ﬁnal allergen challenge. Innate immune
responses to LPS-induced EVs were evaluated 6 h or 24 h
after the sensitization on Day 0.
BAL cellularity
Bronchoalveolar lavage (BAL) cellularity was analyzed as
described previously (7). Brieﬂy, BAL cellularity was deter-
mined by counting 300 inﬂammatory cells after diluting the
cell pellets with 50 ll PBS. Inﬂammatory cells were classiﬁed
as macrophages, lymphocytes, neutrophils or eosinophils.
Lung histology
Lung sections were stained with hematoxylin and eosin
(H&E) after pressure ﬁxation with Streck solution (Streck
Laboratories, La Vista, NE, USA). All sample slides were
compared at the same magniﬁcation. Lung inﬂammation was
assessed based on the degrees of peribronchiolar and perivas-
cular inﬂammation, as described previously (12).
Intracellular staining of lung cells
Cells that were isolated from the lung tissues were incubated
in 48-well plates that were coated with anti-CD3 and anti-
CD28 antibodies (1 lg/ml each; eBioscience) at 37 C for 6 h.
Two hours before the end of incubation, the cells were trea-
ted with brefeldin A (10 lg/ml) for 2 h. The cells were
stained with surface-speciﬁc antibodies (anti-CD3-APC and
anti-CD4-FITC; BD Biosciences, San Jose, CA, USA) for
30 min at 4 C, and then ﬁxed in 100 ll ﬁxation solution at
room temperature for 20 min. The ﬁxed cells were added
with 1 ml permeabilization buffer, centrifuged for 5 min, and
then supernatants were aspirated. The cells were incubated
with anti-IFN-c-PE, anti-IL-17-PE, and anti-IL-4-PE anti-
bodies (BD Biosciences) for 30 min at room temperature,
and analyzed in a FACScalibur ﬂow cytometer (BD Bio-
sciences) using the cellquest software.
Isolation of dendritic cells (DCs) and helper T cells and
in vitro stimulation
Cells that were isolated from lung tissues were stained with
microbead-conjugated anti-CD11c or anti-CD4 (Miltenyi
Biotec, Auburn, CA, USA), and the CD11c
+ cells (DCs) or
CD4
+ cells (helper T cells) were sorted using auto-MACS.
The isolated DCs were incubated with the isolated EVs in
48-well plates for 6 h; thereafter, the conditioned media were
harvested, and then the levels of IL-12p70 and IL-6 were
quantiﬁed. To evaluate cytokine production from helper
T cells, the isolated T cells were incubated in 48-well plates
that were coated with anti-CD3 and anti-CD28 antibodies
(1 lg/ml each; eBioscience) at 37 C for 6 h, and then the
levels of IFN-c, IL-17, and IL-4 were quantiﬁed from condi-
tioned media.
Cytokine assays
The levels of cytokines in the BAL ﬂuids and cell culture
supernatants were measured by ELISA, in accordance with
the manufacturer’s instructions (R&D Systems, Mineapolis,
MN, USA).
Statistical analysis
Analysis of variance (anova) was used to determine the sig-
niﬁcance of differences among all the groups. Signiﬁcant
differences among treatments were assessed by using the
Student’s t-test, anova, and Wilcoxon’s rank sum test. For
multiple comparisons, anova was used initially, and if signiﬁ-
cant differences were found, individual t-tests or Wilcoxon’s
rank sum tests were performed between pairs of groups.
Statistical signiﬁcance was set at P < 0.05.
Results
Production of EVs by airway application of LPS
To evaluate the production of EVs following airway applica-
tion of LPS, 30 ll of PBS with or without 10 lg of LPS were
administered intranasally to naı¨ve BALB/c mice, and then
the BAL ﬂuids were collected 24 h after the last application
(Fig. 1A). The EVs derived from the BAL ﬂuids of the LPS-
treated and PBS-treated mice were found to be spherical in
morphology, as judged from Transmission electron micro-
scopy (TEM) images (Fig. 1B). The amounts (based on pro-
tein concentrations measured using the Bradford assay) and
numbers of EVs were higher in the BAL ﬂuids of the LPS-
treated mice than in those of the PBS-treated mice (Fig. 1C).
The levels of LPS in the EVs isolated from the BAL ﬂuids of
LPS-treated and PBS-treated mice were negligible (Fig. 1D).
The expression of CD81 and ICAM-1 was detected in the
EVs from both groups of mice (Fig. 1E). With regard to the
origin of the EVs, the airway epithelial cell marker protein
surfactant protein B (SP-B) was expressed in the EVs from
both the PBS- and LPS-treated mice; in addition, the expres-
sion of an inﬂammatory cell marker protein, MHC class II,
was noted in EVs from both the PBS- and LPS-inhaled mice
(Fig. 1E,F). As for the expression of a DC marker protein,
CD11c, was absent in EVs from both the PBS- and LPS-
inhaled mice, although CD11b, a marker protein of inﬂam-
matory cells was expressed in EVs from both the two groups
Shin et al. Extracellular vesicles are key intercellular mediators
Allergy 65 (2010) 1256–1265 ª 2010 John Wiley & Sons A/S 1259(Fig. 1F). These data together suggest that the secretion of
EVs can be inducible by airway exposure to LPS, and that
the EVs in the BAL ﬂuid are derived from airway epithelial
cells and inﬂammatory cells other than DCs.
Lung inﬂammation induced by airway sensitization with
allergens and LPS-induced EVs
To evaluate the effects of LPS-induced EVs on the develop-
ment of immune dysfunction to inhaled allergens, naı¨ve
BALB/c mice were sensitized with LPS-induced EVs and an
allergen (OVA), and then challenged with OVA alone (Fig. 2
A). Examination of BAL cellularity showed that inﬁltration
of the lungs by inﬂammatory cells (macrophages, lympho-
cytes, and neutrophils, but not eosinophils) was signiﬁcantly
greater in the mice that were sensitized with OVA plus LPS
(10 lg) or LPS-induced EVs (1 lg) than in the mice that were
sensitized with PBS or PBS-induced EVs (1 lg) (Fig. 2B).
The lung inﬂammatory score, which was based on peribron-
chiolar and perivascular inﬁltration of inﬂammatory cells,
was higher in the mice that were sensitized with LPS or LPS-
induced EVs than in the mice that were sensitized with PBS
or PBS-induced EVs (Fig. 2C). Lung histology revealed that
peribronchiolar and perivascular inﬁltration of inﬂammatory
cells was enhanced in the former two groups, when compared
with the latter two groups (Fig. 2D). These ﬁndings together
suggest that LPS-induced EVs induce airway immune dys-
function to inhaled allergens, although PBS-induced EVs
induce immune tolerance.
Innate immune responses induced by application of LPS-
induced EVs to the airways
The in vitro production levels of TNF-a and IL-6 from
mouse macrophages (RAW264.7 cells) were enhanced by
stimulation with LPS (10 ng/ml) or LPS-induced EVs
(0.5 lg/ml), when compared to stimulation with PBS or PBS-
induced EVs (0.5 lg/ml) (Fig. 3A). Therefore, we evaluated
the effects of LPS-induced EVs on the development of innate
immune responses in vivo. To test this objective, 1 lg of LPS-
induced EVs was applied intranasally to naı¨ve BALB/c mice
(Fig. 3B). Bronchoalveolar lavage cellularity 24 h postappli-
cation was signiﬁcantly increased in the mice that received
LPS-induced EVs, when compared to those that received
PBS-induced EVs (Fig. 3C). Moreover, the in vivo production
levels of TNF-a and IL-6 at 6 h postapplication were higher
in the mice that received LPS-induced EVs than in those
that received PBS-induced EVs (Fig. 3D). Based on the
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Figure 2 Airway sensitization using allergens with LPS-induced
EVs causes noneosinophilic lung inﬂammation. The evaluation was
performed 24 h after the last allergen challenge (n = 5 each group).
(A) Study protocol. (B) Bronchoalveolar lavage (BAL) cellularity. (C)
Inﬂammatory score, which is based on the peribronchiolar and
perivascular inﬁltration of inﬂammatory cells in lung histology. (D)
Representative lung histology (H&E staining, original magniﬁcation
·100). a, PBS; b, LPS; c, EV_PBS; d, EV_LPS. For (B–D) PBS, mice
sensitized with PBS plus Ovalbumin (OVA); LPS, mice sensitized
with LPS (10 lg) plus OVA; EV_PBS, mice sensitized with
PBS-induced EVs (1 lg) plus OVA; EV_LPS, mice sensitized with
LPS (10 lg)-induced EVs (1 lg) plus OVA. *P < 0.05 compared to
the other groups.
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allergens induced mixed Th1 and Th17 cell responses via the
up-regulation of IL-12p70 and IL-6 production, respectively
(7, 8), we evaluated the effects of LPS-induced EVs on the
production of T-cell polarizing cytokines from antigen-
presenting cells. CD11c+ cells (DCs) were isolated from
naı¨ve BALB/c mice, and then stimulated with LPS-induced
EVs or PBS in vitro. The production levels of Th1- and
Th17-polarizing cytokines (IL-12p70 and IL-6, respectively)
were signiﬁcantly higher following stimulation with LPS-
induced EVs (Fig. 3E). Taken together, these data indicate
that EVs secreted in response to LPS cause inﬁltration of
inﬂammatory cells via the up-regulation of pro-inﬂammatory
mediators, such as TNF-a, and modulate adaptive immune
responses via the up-regulation of Th1- and Th17-polarizing
cytokines (IL-12p70 and IL-6, respectively) in antigen-pre-
senting cells.
The roles of LPS and the protein components of LPS-induced
EVs in the development of innate immune responses
To evaluate the role of the LPS in the LPS-induced EVs in
the innate immune responses, the in vitro production levels
of TNF-a and IL-6 in lung macrophages were evaluated
after incubation with LPS-induced EVs, with or without
pretreatment with PMB (an antagonist of LPS). The pro-
duction levels of TNF-a and IL-6 were similar after stimula-
tion with LPS-induced EVs, with or without pretreatment
with PMB, although the LPS-enhanced production of these
cytokines was abolished by pretreatment with PMB (Fig. 4
A). Taken the absence of any LPS in the LPS-induced EVs
into the consideration, this ﬁnding indicates that LPS itself
in host cell-derived EVs plays no role in the development
of the innate immune responses induced by airway LPS
exposure.
Next, we evaluated the roles of protein components in
LPS-induced EVs. To test this, the host cell–derived EVs
were treated with protease K or heating. The production
levels of TNF-a and IL-6 from macrophages enhanced by
LPS-induced EVs were inhibited by pretreatment with pro-
tease K or heating, whereas the production of TNF-a and
IL-6 induced by LPS itself was unaffected by these pretreat-
ments (Fig. 4B). Moreover, confocal and differential inter-
ference contrast (DIC) microscopy images showed that
endocytosis of PBS-induced EVs did not occur, and endo-
cytosis of LPS-induced EVs was blocked by pretreatment
with protease K or heating and by PBS-induced EVs,
although LPS-induced EVs without pretreatment of protease
K or heating were endocytosed into the cytoplasm of the
lung macrophages (Fig. 4C). We also evaluated the roles of
the protein components in LPS-induced EVs on the in vivo
production of pro-inﬂammatory factors. This study showed
that the production of TNF-a and IL-6 enhanced by airway
application of LPS-induced EVs was abolished by pretreat-
ment with protease K or heating (Fig. 4D). These data
together indicate that the protein components in EVs secreted
in response to LPS stimulation play key roles in the develop-
ment of innate immune responses by mediating the endocyto-
sis of signaling factors.
The role of the protein components in LPS-induced EVs on
the development of allergen-speciﬁc adaptive responses
Finally, we evaluated the roles of the protein components in
LPS-induced EVs on the modulation of adaptive immune
responses. To test this, airway allergen sensitization with
A
CD E
B
3500
P < 0.05 250
200
150
100
50
0
P < 0.05 P < 0.05
P < 0.05
3000
2500
2000
1500
1000
500
0
BLANK PBS LPS PBS LPS
EV
BLANK PBS LPS PBS
Evaluation
a PBS
EV_LPS (1 µg) b
Administration LPS
BALB/c
06  h 24 h
EV
T
N
F
-
α
α
 
(
p
g
/
m
l
)
T
N
F
-
α
 
(
p
g
/
m
l
)
I
L
-
6
 
(
p
g
/
m
l
)
I
L
-
1
2
p
7
0
 
(
p
g
/
m
l
)
I
L
-
6
 
(
p
g
/
m
l
)
125
1200
* *
*
*
80
60
40
20
0
30
20
10
0
I
L
-
6
 
(
p
g
/
m
l
)
30
20
10
0
900
600
300
0
PBS EV_LPS PBS EV_LPS PBS EV_LPS PBS EV_LPS
PBS
EV_LPS
*
*
*
100
75
50
Total
Macrophage
Lymphocyte
Neutrophil
Eosinophil
25
0
B
A
L
 
c
e
l
l
s
 
(
×
1
0
3
)
Figure 3 The production levels of pro-inﬂammatory and immuno-
modulating cytokines are up-regulated by airway application of
LPS-induced EVs. (A) Production levels of TNF-a and IL-6 in the
RAW264.7 macrophage cell line after stimulation with PBS, LPS
(10 ng/ml), PBS-induced EVs (0.5 lg/ml) or LPS-induced EVs
(0.5 lg/ml). (B) Protocol for in vivo experiments to evaluate innate
immune responses (n = 5 each group). (C) BAL cellularity 24 h after
airway application of PBS-induced or LPS-induced EVs. (D) In vivo
production levels of TNF-a and IL-6 at 6 h after airway application
of PBS-induced or LPS-induced EVs. (E) Ex vivo production of IL-
12p70 and IL-6 from lung dendritic cells (DCs) 6 h after stimulation
with LPS-induced EVs (0.5 lg/ml). In (C–E) *P < 0.05 compared to
PBS group.
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performed in naı¨ve BALB/c mice, and the responses were
evaluated 24 h after four airway challenges with allergen
alone (Fig. 5A). Analysis of BAL cellularity showed that
inﬁltration into the lungs of inﬂammatory cells (macro-
phages, lymphocytes, and neutrophils) that were enhanced by
sensitization with LPS-induced EVs was signiﬁcantly inhib-
ited by heat pretreatment of the LPS-induced EVs (Fig. 5B).
In terms of the production of T-cell subset cytokines, the
numbers of Th1 (IFN-c) and Th17 (IL-17)-producing T cells
in the lungs were increased by sensitization with OVA plus
LPS-induced EVs, when compared to sensitization with OVA
alone; however, the increases in the numbers of Th1 and
Th17 cells were blocked by heat pretreatment of the LPS-
induced EVs (Fig. 5C). Moreover, the production levels of
IFN-c and IL-17 from the lung CD4 + T cells, which were
increased by sensitization with OVA plus LPS-induced EVs,
were signiﬁcantly inhibited by heat pretreatment of LPS-
induced EVs, whereas the production levels of the Th2 cyto-
kine were similar among the three groups (Fig. 5D). Taken
together, these ﬁndings suggest that the EVs secreted in
response to LPS exposure play key roles in the development
of allergen-speciﬁc Th1 and Th17 cell responses after expo-
sure to LPS-containing allergens, and that the protein com-
ponents of LPS-induced EVs are key players in the
intercellular communication mediated by LPS-induced EVs.
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Figure 4 Protein components of the EVs secreted in response to
LPS play key roles in the mediation of innate immune responses.
(A) The effects of pretreatment with polymyxin B (PMB) (an antago-
nist of LPS) on the in vitro production levels of TNF-a and IL-6 in
RAW264.7 macrophages. (B) The effects of pretreatment with
protease K or heating on the in vitro production levels of TNF-a and
IL-6 in RAW264.7 macrophages. For (A and B) *P < 0.05 compared
to the EV_PBS group; **P < 0.05 compared to the other groups.
(C) Confocal and differential interference contrast (DIC) microscopy
imaging of the effects of pretreatment with protease K or heating
on the endocytosis of LPS-induced EVs into the cytoplasm of
RAW264.7 macrophages. DAPI and cell tracker denote nucleus and
cytoplasmic staining, respectively; DiI indicates lipid labeling. In
both confocal merged and DIC images show that endocytosis does
not occur in LPS-induced EV after pretreatment with protease K or
with heat, although it occurred in LPS-induced EVs without these
treatments. (a: EV_PBS; b: EV_LPS; c: EV_LPS/protease; d:
EV_LPS/heat). (D) Study protocol for in vivo experiments (left
panel), and the effects of pretreatment of proteinase K or heating
on the in vivo production of TNF-a and IL-6 in the airways (right
panel). *P < 0.05 compared to the other groups.
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Immune dysfunction can be mediated by host cells through
the secretion of EVs, in addition to the production of soluble
factors, including cytokines and chemokines (9). Our previ-
ous data indicated that airway exposure to LPS-containing
allergens induced mixed Th1 and Th17 cell responses and
subsequent noneosinophilic lung inﬂammation (7, 8). In the
present study, we show that EVs secreted from host cells,
such as airway epithelial cells and inﬂammatory cells follow-
ing exposure to LPS in vivo induce airway immune dysfunc-
tion toward inhaled allergens; this dysfunction is
characterized by mixed Th1 and Th17 cell responses that
mimic immune responses induced by airway exposure of
LPS-containing allergens. To the best of our knowledge,
these results are the ﬁrst report that host cell–derived EVs
play a key role in the development of airway immune
dysfunction to inhaled allergens.
EVs are spherical structures that are surrounded by a lipid
bilayer and contain hydrophilic soluble components (9). EVs
can be secreted by budding or shedding from the plasma
membranes of platelets (13), tumors (10, 14), neutrophils
(15), and DCs (16); these EVs are also referred to as microve-
sicles, ectosomes, microparticles, and exosomes (9). EVs can
also be secreted following the fusion of internal compart-
ments that contain intraluminal vesicles with the plasma
membrane; such fusion events, which involve the late endocy-
tic multivesicular bodies (MVBs), were ﬁrst observed more
than 20 years ago (17), and the term exosome has been used
to refer to these EVs (18). Electron microscopy studies of
tissue sections from tonsil germinal centers have revealed the
presence of nanometer-size vesicles that bear MHC II and
tetraspanin molecules (19). In addition, EVs have been puri-
ﬁed from several body ﬂuids, such as plasma (20), urine (21),
and BAL ﬂuid (11, 22). In the present study, we puriﬁed EVs
from the BAL ﬂuids of mice that were exposed intranasally
to LPS or PBS. Our EM and biochemical studies revealed
the presence of nanometer-size EVs bearing the tetraspanin
molecule CD81, both in the LPS-treated and PBS-treated
mice. In addition, the amount of EVs was higher in the LPS-
treated mice than in PBS-treated mice, which suggests that
EVs can be induced by inﬂammatory stimuli.
Several types of interaction between EVs and recipient
cells have been proposed based on indirect evidence and
in vitro studies, including adhesion of MVs to the recipient
cell surface through lipids or ligand–receptor interactions and
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Figure 5 Protein components of EVs secreted in response to LPS
are key mediators in the development of mixed Th1 and Th17 cell
responses to inhaled allergens. (A) Study protocol for in vivo experi-
ments to evaluate adaptive immune responses (n = 5 each group).
(B) Bronchoalveolar lavage (BAL) cellularity. *P < 0.05. (C) Intracel-
lular staining for Th1 (IFN-c) and Th17 (IL-17) cytokines: FACS data
were derived from CD3
+ gated lung cells. (D) The levels of Th1
(IFN-c), Th17 (IL-17), and Th2 (IL-4) cytokines in supernatants 6 h
after lung CD4+ T cells were incubated with PBS or anti-CD3 plus
anti-CD28 antibodies. *P < 0.05.
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compartments (9). Recent evidence indicates that ICAM-1 in
EVs derived from mature DCs are captured by binding to a
receptor (lymphocyte function–associated antigen 1, LFA1)
on the DC surface (23). Our present data show that EVs
secreted in response to LPS in the airways also harbor
proteins, including ICAM-1. Moreover, the present confocal
and DIC microscopic imaging showed that protein denatur-
ation by pretreatment with protease K or heating blocked the
endocytosis of EVs in macrophages, which suggests that
protein components in lipid layer of EVs are important for
EV endocytosis in recipient cells, in the context of airway
immune dysfunction by LPS-induced EVs.
A recent study has shown that tumor-cell-derived EVs can
be transferred to T cells, resulting in defective T-cell signal-
ing (24). Our present results show that airway exposure to
LPS enhances the release of EVs, and that LPS-induced EVs
elicit inﬂammation and immune modulation through the
production of pro-inﬂammatory and immunomodulatory
factors. Moreover, we demonstrate that blockade of EV
endocytosis by protein denaturation reverses these deleterious
immune responses. These ﬁndings suggest that EVs derived
from host cells, when exposed to LPS-containing allergens,
deliver signaling ligands to recipient cells, e.g., DCs, thereby
initiating intracellular signaling in recipient cells to induce
innate immune responses that further modulate adaptive
responses.
Although there is some evidence indicating that EVs
puriﬁed in vitro affect immune responses in vivo (25–27), the
roles that EVs secreted in vivo modulate immune responses
remains to be fully determined. Airway exposure to aller-
gens alone induced immune tolerance; a recent report
showed that EVs isolated from the BAL ﬂuids of mice that
were tolerized by airway exposure to allergen alone induced
immune tolerance to inhaled allergens via expression of the
regulatory cytokine TGF-b (11). In contrast, our previous
data indicated that airway sensitization with allergens in
combination with LPS induced mixed Th1 and Th17 cell
responses to allergens, which resulted from LPS-induced
up-regulation of Th1- and Th17-polarizing cytokines (IL-
12p70 and IL-6, respectively) (7, 8) In the present study, we
demonstrated that EVs secreted following airway exposure
to LPS enhanced the production of both IL-12p70 and IL-6
in lung DCs, as well as subsequent mixed Th1 and Th17
cell responses to inhaled allergens. Moreover, blockade of
EV endocytosis by heat-induced protein denaturation
reversed the immune dysfunction to inhaled allergens. Taken
together, these ﬁndings together indicate that EVs represent
an important intercellular communicator in the development
of immune tolerance or immune dysfunction to inhaled
allergens in the airways.
In summary, our present data suggest that EVs secreted by
airway exposure to LPS are key players in the development
of mixed Th1 and Th17 cell responses to inhaled allergens via
the up-regulation of Th1- and Th17-polarizing cytokines, and
that EVs, in addition to soluble factors, are an important
intercellular communication vector between host cells in the
development of airway immune dysfunction in the context of
inhalation of LPS-containing allergens.
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